ArticleTranslational cancer research2024
Construction and validation of a novel web-based nomogram for primary ocular adnexal lymphoma: a real-world analysis based on the Surveillance, Epidemiology, and End Results database.
Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Risk-dependent conditional survival analysis and annual hazard rate of primary ocular adnexal lymphoma.Discover oncology · 2026Article
- Long-Term Survival and Factors Associated with Increased Mortality in Patients with Ocular Adnexal Lymphomas.Cancers · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The occurrence rate of primary ocular adnexal lymphoma (POAL) is relatively low, and estimation of prognosis of these patients poses significant challenges. This study aims to investigate the independent prognostic factors of POAL patients and establish a predictive model to provide clinical data for the formulation of standardized treatment plans. Methods: We conducted a retrospective analysis by extracting data of POAL patients diagnosed between 2000 and 2017 from the Surveillance, Epidemiology, and End Results (SEER) database. The enrolled patients were randomly divided into a training group and a testing group in a 7:3 ratio. To identify independent prognostic factors, we used both univariate and multivariate Cox regression analyses. Conditional survival (CS) pattern of these patients was analyzed. We formulated a nomogram model to forecast survival rates at intervals of 2, 5, 10, and 15 years. The reliability of the model's predictions was assessed through the concordance index (C-index) and the area under the receiver operating characteristic (ROC) curve (AUC). Moreover, we designed an online survival calculator using the nomogram model. Results: The study ultimately analyzed 3,324 patients with POAL, of which 2,327 and 997 were respectively assigned to a training group and a testing group. Important prognostic factors including age, sex, tumor site, tumor histology, coexistence of other malignancy, surgery, radiotherapy (RT), and marital status were identified. Based on these predictors, a novel nomogram model was successfully developed with excellent predictive performance, which can also be accessed on the website: https://helloshinyweb.shinyapps.io/eye_dynamic_nomogram/. The calibration curves demonstrated good consistency between the predicted and actual survival rates. Additionally, the C-index and AUC demonstrated good discriminative ability. Conclusions: This study has successfully developed and validated a prognostic nomogram model that accurately predicts the survival rate of patients with POAL. The model proves invaluable in enabling clinical doctors to assess patients' risk factors and formulate personalized treatment strategies, thereby enhancing survival assessment and clinical management for POAL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.